NCT03311542 is a clinical trial of pembrolizumab in Melanoma (Skin), sponsored by Center Trials & Treatment.

Who is sponsoring NCT03311542?

NCT03311542 is sponsored by Center Trials & Treatment.

What drugs are being tested in NCT03311542?

Interventions in NCT03311542: pembrolizumab.

What condition does NCT03311542 study?

NCT03311542 studies Melanoma (Skin), Melanoma Recurrent, Glioblastoma Multiforme, Glioblastoma by Gene Expression Profile, Glioma of Brain.

Is NCT03311542 still recruiting?

NCT03311542 is currently no longer available. Last updated 10 January 2018.

Last reviewed 2018-01-10 · How we verify

NCT03311542

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Expanded Access for Pembrolizumab (MK-3475)

NO LONGER AVAILABLE Last updated 10 January 2018

What this trial tests

trial testing pembrolizumab in Melanoma (Skin). No longer available.

Quick facts

Lead sponsor	Center Trials & Treatment
Status	NO LONGER AVAILABLE
Study type	EXPANDED_ACCESS
Sites	4 locations across Hong Kong, Uzbekistan, Tajikistan, Belarus

Drugs / interventions tested

pembrolizumab (pembrolizumab) — full drug profile →

Conditions studied

Melanoma (Skin) — all drugs for Melanoma (Skin) →
Melanoma Recurrent — all drugs for Melanoma Recurrent →
Glioblastoma Multiforme — all drugs for Glioblastoma Multiforme →
Glioblastoma by Gene Expression Profile — all drugs for Glioblastoma by Gene Expression Profile →

Sponsor

Center Trials & Treatment — full company profile →

Who can join

Adults 18 to 80, any sex, with Melanoma (Skin) or Melanoma Recurrent. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an expanded access program (EAP) for patient with Melanoma and Glioblastoma who have progressed after prior Protocol therapy including Bevacizumab, Temozolomide ( TMZ ), Ipilimumab, BRAF and MEK inhibitors. The patients whose tumors are EGFR, MET or ALK positive should first receive an EFGR or ALK inhibitor, respectively, prior to treatment with pembrolizumab.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Immune Checkpoints and Innovative Therapies in Glioblastoma.
Romani M, Pistillo MP, Carosio R, Morabito A, et al · · 2018 · cited 70× · PMID 30406030 · DOI 10.3389/fonc.2018.00464
Nanomedicine and Immunotherapy: A Step Further towards Precision Medicine for Glioblastoma.
Šamec N, Zottel A, Videtič Paska A, Jovčevska I. · · 2020 · cited 30× · PMID 31979318 · DOI 10.3390/molecules25030490
Immune Checkpoint Inhibitors in Glioblastoma IDHwt Treatment: A Systematic Review.
Baskaran AB, Kozel OA, Venkatesh O, Wainwright DA, et al · · 2024 · cited 5× · PMID 39766048 · DOI 10.3390/cancers16244148

Verify or expand the search:

Other trials of pembrolizumab

Trials testing the same drug.

NCT07223424 — Patient Preference for Subcutaneous vs. Intravenous Immune Therapy · Phase 2 · recruiting
NCT06899126 — Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-sm · Phase 3 · recruiting
NCT06161545 — Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcino · Phase 2 · recruiting
NCT05879484 — Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Ca · Phase 1, PHASE2 · withdrawn
NCT06682806 — A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 · Phase 2 · terminated

Other recruiting trials for Melanoma (Skin)

Currently open trials in the same condition.

NCT06643286 — Evaluation of a Personalised Survivorship Care Plan App for Patients With Melanoma · NA · recruiting
NCT06298734 — High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial · NA · recruiting
NCT05704647 — Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases · Phase 2 · recruiting
NCT05492682 — START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer · Phase 1 · active not recruiting
NCT05649683 — Immunological Functionnal Test Validation to Predict Melanoma Metastatic Patient Response to Checkpoint Inhibitors · NA · recruiting

Other Center Trials & Treatment trials

Trials by the same sponsor.

NCT03426254 — Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients W · Phase 1 · withdrawn
NCT05104840 — A Randomized Study to Determine the Expression of the Furin Protein in Patients With SARS-CoV-2 and Vaccinated Against C · terminated
NCT03275558 — Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma · Phase 1 · withdrawn
NCT03460782 — An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas · no longer available

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03311542 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Center Trials & Treatment
Last refreshed: 10 January 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03311542.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing